Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolDecCDintra: Tolerogenic Dendritic Cells in Refractory Crohn's Disease
NCT02622763Phase 1Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2015
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in Crohn's disease (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Number of adverse events at 12 weeks and Proportion of patients with clinical response at 12 weeks. Started Nov 2015; status: terminated.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02622763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622763.